The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
IL28B Genotype Is Associated With Differential Expression of Intrahepatic Interferon-Stimulated Genes in Patients With Chronic Hepatitis C
Open accessAbstract
Genetic variation in the IL28B (interleukin 28B; interferon lambda 3) region has been associated with sustained virological response (SVR) rates in patients with chronic hepati-tis C (CHC) who were treated with peginterferon- a and ribavirin. We hypothesized that IL28B polymorphism is associated with intrahepatic expression of interferon-stimulated genes (ISGs), known to influence treatment outcome. IL28B genotyping (rs12979860) and whole-genome RNA expression were performed using liver biopsies from 61 North American patients with CHC. After correction for multiple testing (false discovery rate < 0.10), 164 transcripts were found to be differentially expressed by IL28B -type. The inter-feron signaling pathway was the most enriched canonical pathway differentially expressed by IL28B -type ( P < 10 25 ), with most genes showing higher expression in livers of individ-uals carrying the poor-response IL28B -type. In 25 patients for which treatment response data were available, IL28B -type was associated with SVR ( P 5 0.0054). ISG expression was also associated with SVR; however, this was not independent of IL28B -type. Analysis of miR-122 expression in liver biopsies showed reduced miR-122 levels associated with poorer treatment outcome, independently of IL28B -type. No association was observed between IL28B -type and levels of liver IL28B or IL28A messenger RNA expression. IL28B protein sequence variants associated with rs12979860 were therefore investigated in vitro : no differences in ISG induction or inhibition of HCV replication were observed in Huh7.5 cells. Conclusion: The good response IL28B variant was strongly associated with lower level ISG expression. The results suggest that IL28B genotype may explain the relationship between hepatic ISG expression and HCV treatment outcome, and this is independent of miR-122 expression. IL28B -type was not associated with intrahepatic IL28B messenger RNA expression in vivo . Further investigation of the precise molecular mechanism(s) by which IL28B genetic variation influences HCV outcomes is warranted. (HEPATOLOGY 2010;52:1888-1896)
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The HCV Life Cycle: In vitro Tissue Culture Systems and Therapeutic Targets
Gerold, G., & Pietschmann, T. (2014) · Digestive Diseases · doi:10.1159/000360830 · Cited by 4,854
An Algorithm for the Grading of Activity in Chronic Hepatitis C
Bedossa, P., & Poynard, T. (1996) · Hepatology · doi:10.1002/hep.510240201 · Cited by 4,088
Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance
Ge, D., Fellay, J., Thompson, A. J., Simon, J. S., Shianna, K. V., Urban, T. J., Heinzen, E. L., Qiu, P., Bertelsen, A. H., Muir, A. J., et al. (2009) · Nature · doi:10.1038/nature08309 · Cited by 3,514
Self-citationDiagnosis, management, and treatment of hepatitis C: An update # † ‡
Ghany, M. G., Strader, D. B., Thomas, D. L., & Seeff, L. B. (2009) · Hepatology · doi:10.1002/hep.22759 · Cited by 2,973
Modulation of Hepatitis C Virus RNA Abundance by a Liver-Specific MicroRNA
Jopling, C. L., Yi, M., Lancaster, A. M., Lemon, S. M., & Sarnow, P. (2005) · Science · doi:10.1126/science.1113329 · Cited by 2,521
Interferon-inducible antiviral effectors
Sadler, A. J., & Williams, B. R. G. (2008) · Nature Reviews Immunology · doi:10.1038/nri2314 · Cited by 2,160
Genetic variation in IL28B and spontaneous clearance of hepatitis C virus
Thomas, D. L., Thio, C. L., Martin, M. P., Qi, Y., Ge, D., O’hUigin, C., Kidd, J., Kidd, K., Khakoo, S. I., Alexander, G., et al. (2009) · Nature · doi:10.1038/nature08463 · Cited by 2,150
Self-citationTanaka, Y., Nishida, N., Sugiyama, M., Kurosaki, M., Matsuura, K., Sakamoto, N., Nakagawa, M., Korenaga, M., Hino, K., Hige, S., et al. (2009) · Nature Genetics · doi:10.1038/ng.449 · Cited by 2,141
IL28B is associated with response to chronic hepatitis C interferon-α and ribavirin therapy
Study, F. T. H. C., Suppiah, V., Moldovan, M., Ahlenstiel, G., Berg, T., Weltman, M., Abate, M. L., Bassendine, M., Spengler, U., Dore, G. J., et al. (2009) · Nature Genetics · doi:10.1038/ng.447 · Cited by 1,826
Therapeutic silencing of microRNA-122 in primates with chronic hepatitis C virus infection
Lanford, R. E., Hildebrandt-Eriksen, E. S., Petri, A., Persson, R., Lindow, M., Munk, M. E., Kauppinen, S., & Ørum, H. (2010) · Science · doi:10.1126/science.1178178 · Cited by 1,459
Efficient Initiation of HCV RNA Replication in Cell Culture
Blight, K. J., Kolykhalov, A. A., & Rice, C. M. (2000) · Science · doi:10.1126/science.290.5498.1972 · Cited by 1,412
Rauch, A., Kutalik, Z., Descombes, P., Cai, T., Di Iulio, J., Mueller, T., Bochud, M., Battegay, M., Bernasconi, E., Borovicka, J., et al. (2010) · Gastroenterology · doi:10.1053/j.gastro.2009.12.056 · Cited by 1,137
Interferon signaling and treatment outcome in chronic hepatitis C
Sarasin-Filipowicz, M., Oakeley, E. J., Duong, F. H. T., Christen, V., Terracciano, L., Filipowicz, W., & Heim, M. H. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0707882105 · Cited by 642
Chen, L., Borozan, I., Feld, J., Sun, J., Tannis, L.-L., Coltescu, C., Heathcote, J., Edwards, A. M., & McGilvray, I. D. (2005) · Gastroenterology · doi:10.1053/j.gastro.2005.01.059 · Cited by 453
Honda, M., Sakai, A., Yamashita, T., Nakamoto, Y., Mizukoshi, E., Sakai, Y., Yamashita, T., Nakamura, M., Shirasaki, T., Horimoto, K., et al. (2010) · Gastroenterology · doi:10.1053/j.gastro.2010.04.049 · Cited by 400
Sarasin-Filipowicz, M., Krol, J., Markiewicz, I., Heim, M. H., & Filipowicz, W. (2009) · Nature Medicine · doi:10.1038/nm.1902 · Cited by 304
Feld, J. J., Nanda, S., Huang, Y., Chen, W., Cam, M., Pusek, S. N., Schweigler, L. M., Theodore, D., Zacks, S. L., Liang, J. T., et al. (2007) · Hepatology · doi:10.1002/hep.21853 · Cited by 265
Zeremski, M., Petrovic, L. M., Chiriboga, L., Brown, Q. B., Yee, H. T., Kinkhabwala, M., Jacobson, I. M., Dimova, R., Markatou, M., & Talal, A. H. (2008) · Hepatology · doi:10.1002/hep.22500 · Cited by 216
Asselah, T., Bieche, I., Narguet, S., Sabbagh, A., Laurendeau, I., Ripault, M.-P., Boyer, N., Martinot-Peignoux, M., Valla, D., Vidaud, M., et al. (2008) · Gut · doi:10.1136/gut.2007.128611 · Cited by 208
The role of chemokines as inflammatory mediators in chronic hepatitis C virus infection
Zeremski, M., Petrovic, L. M., & Talal, A. H. (2007) · Journal of Viral Hepatitis · doi:10.1111/j.1365-2893.2006.00838.x · Cited by 188
Plasma chemokine levels correlate with the outcome of antiviral therapy in patients with hepatitis C
Butera, D., Marukian, S., Iwamaye, A. E., Hembrador, E., Chambers, T. J., Di Bisceglie, A. M., Charles, E. D., Talal, A. H., Jacobson, I. M., Rice, C. M., et al. (2005) · Blood · doi:10.1182/blood-2005-01-0126 · Cited by 178
Li, J. H., Lao, X. Q., Tillmann, H. L., Rowell, J. V., Patel, K., Thompson, A., Suchindran, S., Muir, A. J., Guyton, J. R., Gardner, S. D., et al. (2010) · Hepatology · doi:10.1002/hep.23592 · Cited by 118
Self-citationLu, J., Tay, P. N., Kon, O. L., et al. (1996) · Biochemical Journal · doi:10.1042/bj3130473 · Cited by 110
Chen, L., Borozan, I., Sun, J., Guindi, M. M., Fischer, S. E., Feld, J. J., Anand, N., Heathcote, J., Edwards, A. M., & McGilvray, I. D. (2009) · Gastroenterology · doi:10.1053/j.gastro.2009.10.046 · Cited by 105
Lu, J., Le, Y., Kon, O. L., et al. (1996) · Immunology · doi:10.1046/j.1365-2567.1996.d01-732.x · Cited by 85
Lanford, R. E., Guerra, B., Bigger, C. B., Lee, H., Chavez, D., & Brasky, K. M. (2007) · Hepatology · doi:10.1002/hep.21776 · Cited by 61
Florholmen, J. R., Kristiansen, M. G., Steigen, S. E., et al. (2010) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2010.03206.x · Cited by 19
Cited by
Treatment of HCV Infection by Targeting MicroRNA
Janssen, H. L. A., Reesink, H. W., Lawitz, E. J., Zeuzem, S., Rodriguez-Torres, M., Patel, K., van der Meer, A. J., Patick, A. K., Chen, A., Zhou, Y., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1209026 · Cited by 2,204
Self-citationProkunina-Olsson, L., Muchmore, B., Tang, W., Pfeiffer, R. M., Park, H., Dickensheets, H., Hergott, D., Porter-Gill, P., Mumy, A., Kohaar, I., et al. (2013) · Nature Genetics · doi:10.1038/ng.2521 · Cited by 928
Interferon-λ: Immune Functions at Barrier Surfaces and Beyond
Lazear, H. M., Nice, T. J., & Diamond, M. S. (2015) · Immunity · doi:10.1016/j.immuni.2015.07.001 · Cited by 480
Guarding the frontiers: the biology of type III interferons
Wack, A., Terczyńska-Dyla, E., & Hartmann, R. (2015) · Nature Immunology · doi:10.1038/ni.3212 · Cited by 364
Regulation of hepatic innate immunity by hepatitis C virus
Horner, S. M., & Gale, M. (2013) · Nature Medicine · doi:10.1038/nm.3253 · Cited by 278
Metadata
- Authors
- Urban, T. J., Thompson, A. J., Bradrick, S. S., Fellay, J., Schuppan, D., Cronin, K. D., Hong, L., McKenzie, A., Patel, K., Shianna, K. V., McHutchison, J. G., Goldstein, D. B., & Afdhal, N.
- Venue
- Hepatology
- Published
- 2010-12
- Volume
- 52
- Issue
- 6
- Pages
- 1888-1896
- ISSN
- 0270-9139 (ISSN-L)
- OpenAlex
- W2156236127
- Cited by
- 361
- References
- 27
- FWCI
- 37.07
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.